BD to acquire Edwards Lifesciences' Critical Care Product Group for $4.2 B

03rd June, 2024

Critical Care to operate as a separate business unit within BD's medical segment, based in Irvine, California

BD (Becton, Dickinson and Company), a leading global medical technology company, and Edwards Lifesciences have announced a definitive agreement under which BD will acquire Edwards' Critical Care product group, a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

Critical Care is a high-growth, innovative industry leader in advanced patient monitoring with advanced artificial intelligence (AI) algorithms serving millions of patients globally. Critical Care invented the hemodynamic monitoring category, and its solutions are currently used in more than 10,000 hospitals globally to better understand the cardiovascular condition in real-time for critically ill patients, which helps improve outcomes. Hemodynamic monitoring and medication management technologies are often used simultaneously in the operating room or intensive care units, creating longer-term opportunities for meaningful innovation and interoperability across the care continuum. Critical Care has approximately 4,500 employees with most based in Irvine, California, US. In 2023, the business generated more than $900 million in revenue.

Critical Care's portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors and monitors. Its smart technologies are driven by advanced data analytics with machine learning and AI-based predictive and prescriptive algorithms to help clinicians better understand current and future patient conditions and provide clinical decision support tools.

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer